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FMD Research – historical breakthroughs 
Our ability to control a disease is constrained by the tools available 
  
 
 
 
 
3 
FMD Research – historical breakthroughs 
Disease 
control 
Our ability to control a disease is restrained by the tools available 
Veterinary services 
-Coordinated control 
Immunisation 
-Passive 
-Vaccines 
-Mass produced vaccines 
-Improved & stable vaccines 
 
Diagnostics 
-DIVA methods 
-Phylogenetics & typing 
-Immune correlates 
Epidemiology 
-Strategies 
-Modelling 
Progress accelerates and stagnates as 
breakthroughs are made • Control FMD where control not previously possible 
• Same level of control but more efficient (time, cost) 
• Increased certainty in disease/infection status (trade, rapid detection) 
• Increased understanding 
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Global control with current technologies 
  
 
 
 
 
5 
Global control with current technologies 
Countries with 
outbreaks in free zones 
Jan 2005-Aug 2014 
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• Free countries 
• Preparedness, early detection and control 
• Free and endemic with vaccination 
• Vaccine immunity - duration, match 
• Vaccine stability, safety, strategy & evaluation 
• Proving freedom  
• Limited control activities 
• Impact estimation 
• Feasibility of FMD control – effectiveness, cost, convenience/compliance 
 
 
FMD research needs 
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• Literature review – FMD publications 2011-14 
• Institute updates on current research 
• Contacted >50 FMD research institutes (GFRA/EuFMD) 
• Response from 33 
• Europe – 10 (30%) 
• North America – 5 (15%) 
• South America – 2 (6%) 
• Asia – 6 (3) (18%) 
• Africa – 8 (24%) 
• Australia/New Zealand – 2 (6%) 
• Review by GFRA experts 
FMD research review - approach 
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Peer-reviewed publications June 2011-14 
Research Category Papers (n) 
Epidemiology 116 (23%) 
Vaccines 94 (19%) 
Pathogenesis 74 (15%) 
Molecular biology 57 (11%) 
Diagnostics 55 (11%) 
Immunology 50 (10%) 
Policy, preparedness and trade 38 (8%) 
Wildlife 19 (4%) 
Vaccine evaluation 
 (quality, efficacy, effectiveness) 
16 (3%) 
Other 15 (3%) 
Economics 14 (3%) 
Biotherapeutics 13 (3%) 
Total 505 (100%) 
Half modelling 
studies 
Economic studies 
needed by those 
with least resources 
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Vaccines – The ideal FMD vaccine 
 
• Effective, rapid and long-lasting protection with one inoculation 
• Prevents viral transmission & carrier state 
• Allow differentiation of infected from vaccinated animals (DIVA) 
• Produced without the need for virulent FMDV 
• Protection against multiple serotypes 
• Stable antigen – long shelf life 
• Reasonable cost to enable eradication programs 
Gay et al. 2013 
Report: Key findings 
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• Progress 
• Empty capsid vaccines 
• Adenovirus vector, Baculovirus expression system  
• Inactivated molecular chimeric vaccine 
• Early stages but: 
• Produced without live FMDV 
• Improved DIVA 
• Improved stability 
• Gaps 
• Cost 
• Duration and breadth of immunity – important for endemic settings 
• African vaccine strains- SAT 2 vaccines 
• Lack of standardised approach to novel vaccine evaluation 
Vaccines 
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• Progress 
• Faster, cheaper, simpler diagnostics 
• RT-LAMP, high-speed, portable PCR, sequencing 
• Simple pen-side tests 
• More powerful molecular techniques 
• Next generation sequencing 
• Tools for molecular epidemiology 
• Better understanding of within-host virus evolution, between animal transmission, 
population level virus ecology 
• Gaps 
• Continued progress in rapid/simple diagnostics & molecular techniques 
• Vaccine matching – beyond small scale, imprecise antibody assays 
• Wildlife diagnostics & sampling (under investigation) 
Diagnostics 
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• Progress 
• Modelling approaches developed & widely used 
• Importance of field evaluation of control programmes 
• Alternatives to stamping out [vaccinate-to-live] 
• Incentivisation through commodity-based trade 
• Gaps 
• Evaluation & validation of models 
• Practicalities of vaccinate-to-live 
• Safety & acceptance of commodity-based trade 
• Strategies & guidance for endemic countries 
• Knowledge sharing – South America 
Disease management 
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1. Improve readiness for FMD crisis management by Members 
• Vaccine matching tests & measures of cross-protective immunity 
• Further development of modelling approaches for policy guidance 
• Improved, cross-protective, DIVA vaccines 
 
2. Reduce risk to Members of an FMD incursion from the neighbourhood 
• Cheaper vaccines with long lasting, broad spectrum immunity 
• Capacity building – technical skills, regional collaboration, vaccine quality assurance 
• Improved knowledge and monitoring of wildlife and illegal trade 
 
3. Promote the global FMD control strategy 
• Cheaper vaccines with long lasting, broad spectrum immunity [SAT 2, African strains] 
• Can FMD be controlled with current vaccines without effective biosecurity? 
• Economic impact of FMD &  when are control efforts cost-effective 
• Evaluation of commodity based trade as a safe way of exporting from wildlife FMD endemic areas 
 
• Progress in genetic and molecular technologies will benefit all 
EuFMD – 3 Pillars: Research needs 
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3. Promote the global FMD control strategy 
• Cheaper vaccines with long lasting, broad spectrum immunity 
• Can FMD be controlled with current vaccines without effective biosecurity? 
• Economic impact of FMD &  when are control efforts cost-effective 
• Evaluation of commodity based trade as a safe way of exporting from wildlife FMD endemic areas 
 
• Progress in genetic and molecular technologies is crucial & will benefit all 
EuFMD – 3 Pillars: Research needs 
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“Cause for optimism, but much to be done” 
Conclusion 
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